Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19442308 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1EGFRLMNABTK | |
| SCHEMBL19669740 | 0.87 | LMNA (0.38) | SMN1; SMN2ALDH1A1EGFRLMNABTK | |
| SCHEMBL19912771 | 0.87 | PKM (0.36) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 | |
| SCHEMBL24637162 | 0.85 | EGFR (0.34) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 | |
| SCHEMBL15600841 | 0.85 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1EGFRBTKMEN1 | |
| SCHEMBL19669759 | 0.85 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1EGFRBTKELANE | |
| SCHEMBL20235763 | 0.84 | ACKR3 (0.35) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 | |
| SCHEMBL15601163 | 0.84 | KMT2A (0.36) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 | |
| SCHEMBL19669738 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 | |
| SCHEMBL15600836 | 0.83 | SIGMAR1 (0.41) | SMN1; SMN2ALDH1A1EGFRLMNAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | AURIGENE ONCOLOGY LIMITED (IN) | 2024-01-18 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-16 | — | — | US | disclosed |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-08-20 | — | — | US | disclosed |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-06-23 | — | — | US | disclosed |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-06-07 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250062-A9 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | SMN1; SMN2 1062/4885ALDH1A1 4813/4885EGFR 2065/4885 |
| US-11174232-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | SMN1; SMN2 1062/4885ALDH1A1 4813/4885EGFR 2065/4885 |
| US-20240016811-A1 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-MICROTUBULE AGENT | CDK7, CDK17, HDAC7 | SMN1; SMN2 1366/4885ALDH1A1 2661/4885EGFR 2251/4885 |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | SMN1; SMN2 1504/4885ALDH1A1 4435/4885EGFR 2707/4885 |
| US-20180155293-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK17, CDK1 | SMN1; SMN2 1068/4885ALDH1A1 4829/4885EGFR 1969/4885 |
| US-10689347-B2 | Substituted heterocyclyl derivatives as CDK inhibitors | CDK19, CDK9, CDK1 | SMN1; SMN2 1062/4885ALDH1A1 4813/4885EGFR 2065/4885 |
| US-20200262793-A1 | Substituted Heterocyclyl Derivatives as CDK Inhibitors | CDK19, CDK9, CDK1 | SMN1; SMN2 1062/4885ALDH1A1 4813/4885EGFR 2065/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | SMN1; SMN2 1504/4885ALDH1A1 4435/4885EGFR 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.